The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00252018|
Recruitment Status : Completed
First Posted : November 11, 2005
Last Update Posted : May 14, 2008
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The purpose of this study is to investigate whether a daily intake of dried broccoli sprouts will improve the endothelial function of the participants as measured by Flow mediated dilation (FMD)
The dried sprouts are chosen because broccoli sprouts are known as containing large amounts af the glucosinolate glucoraphanin which in vitro and in animal models has been shown to have a positive effect on the endothelium as measured by NO release.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Hypertension Hypercholesterolemia Cardiovascular Disease||Behavioral: Daily intake of broccoli sprouts||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease.|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||March 2007|
|Actual Study Completion Date :||March 2007|
- Improvement of endothelial function as measured by FMD
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients suffering from hypertension, having a diastolic blood pressure of above 90 mm Hg or a systolic blood pressure of more than 140 mm Hg.
- Patients suffering from NIDDM, according to present criteria for diagnosis of NIDDM:
- People with dyslipidemia (combination of total cholesterol above 5, LDL cholesterol above 3 and HDL cholesterol below 1.1)
- Healthy controls suffering from none of the above conditions, but otherwise (age, sex, BMI and lifestyle) corresponding to the patient groups.
- Patients under the age of 18 at inclusion in the study.
- Pregnant or breastfeeding women
- Women of childbearing age with no safe method of contraception
- Patients receiving vitamin K-antagonists (coumarine, marcoumar etc)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252018
|Copenhagen, Denmark, 2400|
|Study Chair:||Christian Torp-Pedersen, MD||Bispebjerg Hospital Department of Cardiology|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Other Study ID Numbers:||
|First Posted:||November 11, 2005 Key Record Dates|
|Last Update Posted:||May 14, 2008|
|Last Verified:||May 2008|
Flow mediated dilation
Lipid Metabolism Disorders